2 companies
argenx
Market Cap: €35.1b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€575.60
7D
6.4%
1Y
58.4%
UCB
Market Cap: €32.2b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€169.20
7D
13.2%
1Y
41.8%